Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

NCT06321341

Status	RECRUITING
Phase	Phase 4
Sponsor	Valenta Pharm JSC
Enrollment	160 participants

Key Eligibility Criteria

Inclusion (65)

- Patient signed and dated the Informed Consent Form.
- Males and females e18 to d 65 years of age inclusive at the time of signing the Informed Consent Form.
- Clinical diagnosis: G90.8 Other disorders of autonomic nervous system or G90.9 Disorder of autonomic nervous system, unspecified.
- Diagnosed chronic functional vertigo per Barani Society criteria: total DHI score e 31 points; mean MVS score e 1.5 points.
- For women of childbearing potential, a negative pregnancy test and consent to use an authorized method of contraception throughout the entire period of study participation, starting from Visit 0, and for 3 weeks after the end of the study; for men, consent to use an authorized method of contraception throughout the entire period of study participation and for 3 weeks after the end of the study.

... and 60 more (see full listing online)

Exclusion (2)

- The patient's decision to discontinue participation in the study.
- A decision by the investigator that continued participation in the study is contrary to the patient's best interests.

Locations (4 total)

Central Clinic LLC, Bryansk, Russia

Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation, Kirov, Russia

State Budgetary Institution of Healthcare of the City of Moscow "V.P. Demikhov City Clinical Hospital of the Department of Healthcare of the City of Moscow", Moscow, Russia

... and 1 more locations